InDex Pharmaceuticals Holding AB (FLERIE) AI Stock Analysis

• Market Cap: kr3.17B
• Dividend Yield: N/A
• Average Volume (3M): 23.47K
• Price to Earnings (P/E): 0.3
• Beta (1Y): -0.06
• Revenue Growth: -88.79%
• EPS Growth: N/A
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): 155.96
• Shares Outstanding: 78,066,410
• 10 Day Avg. Volume: 28,373
• 30 Day Avg. Volume: 23,469
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

InDex Pharmaceuticals Holding AB shows significant financial challenges with negative profitability and cash flow issues. Technical analysis indicates a bearish trend with weak momentum. Valuation metrics are difficult to interpret due to low earnings, but the lack of dividend yield aligns with a growth-focused biotech strategy. The stock score reflects these mixed but predominantly negative factors.

InDex Pharmaceuticals Holding AB Business Overview & Revenue Model

Company Description

InDex Pharmaceuticals Holding AB (FLERIE) is a biopharmaceutical company based in Sweden, dedicated to the development of innovative pharmaceutical products targeting immunological diseases. The company's core focus is on its lead product candidate, cobitolimod, an anti-inflammatory drug intended for the treatment of ulcerative colitis. InDex aims to address significant unmet medical needs by advancing cobitolimod through clinical development and eventually bringing it to market.

How the Company Makes Money

InDex Pharmaceuticals generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company's key revenue stream is expected to come from the successful development, approval, and subsequent sales of cobitolimod. InDex may also enter into strategic partnerships or licensing agreements with larger pharmaceutical companies to co-develop or market cobitolimod, which could provide additional revenue in the form of upfront payments, milestones, and royalties. Additionally, the company may seek funding through public or private investments to support its research and development activities.

InDex Pharmaceuticals Holding AB Financial Statement Overview

Summary

InDex Pharmaceuticals Holding AB faces significant challenges in profitability and cash flow, typical of emerging biotechnology firms. While the balance sheet reflects strong equity and low leverage, the income statement and cash flow statement reveal operational difficulties. Continued dependence on external financing may pose a risk if revenue generation does not improve.

Income Statement

The company has struggled with profitability, as evidenced by negative EBIT and net income. The gross profit margin is nonexistent with consistently negative gross profit. Revenue growth is stagnant, with minimal revenue in recent years. These factors indicate significant challenges in operational efficiency and market penetration.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, indicating financial stability. The debt-to-equity ratio is minimal, suggesting low leverage and reduced financial risk. However, asset growth has not been matched by revenue growth, which could indicate inefficiencies in asset utilization.

Cash Flow

Operating and free cash flows are persistently negative, highlighting cash flow challenges. The high financing cash flow suggests reliance on external funding, which may not be sustainable long-term. The operating cash flow to net income ratio is poor, indicating inefficiencies in converting earnings into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
100.00K	100.00K	97.50M	0.00	0.00	35.00K
	Gross Profit
-18.00M	100.00K	93.35M	-1.07M	-1.25M	-57.73M
	EBIT
-357.00M	-275.00M	-107.37M	-151.11M	-115.63M	-57.73M
	EBITDA
-136.60M	-225.90M	-93.82M	-99.15M	-101.66M	-56.11M
	Net Income Common Stockholders
-329.50M	-228.00M	-95.27M	-100.33M	-103.04M	-57.42M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
802.10M	865.10M	294.27M	344.93M	428.45M	53.83M
	Total Assets
3.96B	4.22B	299.39M	351.34M	445.20M	61.18M
	Total Debt
800.00K	800.00K	2.30M	3.25M	1.28M	2.34M
	Net Debt
-801.30M	-864.30M	-291.97M	-341.68M	-427.17M	-51.49M
	Total Liabilities
10.80M	25.30M	60.50M	17.38M	11.16M	11.86M
	Stockholders Equity
3.95B	4.20B	238.88M	333.96M	434.04M	49.33M
Cash Flow		Free Cash Flow
-1.51M	-17.00M	-37.98M	-129.44M	-124.06M	-71.56M
	Operating Cash Flow
-1.51M	-17.00M	-37.98M	-129.44M	-124.06M	-70.65M
	Investing Cash Flow
-65.90M	-19.80M	-625.20M	0.00	0.00	-909.00K
	Financing Cash Flow
572.07M	571.90M	634.70M	-818.00K	486.39M	-1.40M

InDex Pharmaceuticals Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 40.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLERIE, the sentiment is Negative. The current price of 40.6 is below the 20-day moving average (MA) of 41.66, below the 50-day MA of 44.20, and below the 200-day MA of 45.26, indicating a bearish trend. The MACD of -1.17 indicates Negative momentum. The RSI at 39.02 is Neutral, neither overbought nor oversold. The STOCH value of 24.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLERIE.

InDex Pharmaceuticals Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
FLERIE	47 Neutral	kr3.17B	0.26	-3.68%	―	-88.79%	―
VICO	45 Neutral	€1.74B	―	-20.96%	―	―	63.85%
BINV	43 Neutral	$1.93B	―	-38.56%	―	-37.47%	-29.99%
SYNACT	40 Neutral	kr978.22M	―	-43.97%	―	―	67.70%
HNSA	39 Underperform	kr1.46B	―		―	9.53%	41.19%
XSPRAY	34 Underperform	€1.08B	―	-42.78%	―	―	-19.44%